Dr. Avyakta Kallam, MBBS, MD

Dr. Kallam practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Kallam's NPI, 1124307327, was assigned on August 5, 2011. Dr. Kallam graduated from Osmania Medical College NTR UHS in 2009. Dr. Kallam holds California license A133163.

Dr. Kallam's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Kallam's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Kallam to 1 more other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kallam practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Kallam's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Kallam is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kallam's licenses on file in 3 states: California, Nebraska and Georgia.

Dmand AI lists chronic anemia, chronic leukemia, deep vein thrombosis (DVT), lymphoma and multiple myeloma among the conditions Dr. Kallam treats.

CMS data shows 674 Medicare services from Dr. Kallam across 7 procedure codes in 2024, for 147 Medicare patients. Medicare paid $56,833 for them.

CMS counts 147 Medicare patients who saw Dr. Kallam in 2024. The largest group is 65 to 74, with 58 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 37% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kallam's median patient age at 67, with 43% women.

In 2024, Dr. Kallam wrote 112 Medicare Part D claims for 23 patients. 63% of them were for generic drugs. CMS names the drug for 73 of them, across 4 drugs with 11 or more claims each, at $588 in total drug cost. In 2022, CMS named 155 claims across 8 drugs.

Dr. Kallam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kallam as offering telehealth.

Dmand AI links 35 papers to Dr. Kallam, published from 2014 to 2024. 2019 was the busiest year, with 5. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Hodgkin Disease and Leukemia, Lymphocytic, Chronic, B-Cell. Dr. Kallam has published most often in Clin Lymphoma Myeloma Leuk. Dr. Kallam's most frequent co-authors are James O. Armitage, MD, Philip J. Bierman, MD and Krishna Gundabolu, MD.

Dmand AI links Dr. Kallam to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Hodgkin Disease, Lymphoma, T-Cell and Lymphoma.

CMS Open Payments shows 27 general payments to Dr. Kallam from 12 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Genmab U.S., Inc. paid the most, $4,915.

Dr. Kallam graduated from Osmania Medical College NTR UHS in 2009.

Dr. Kallam is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.